
HPVã¯ã¯ãã³ãã¬ãŒãã·ã«ãã¯ããã©ã»ã矀ã«ççé£å¡©æ°Žã䜿ããªãã£ã!?
ã¢ã¡ãªã«ã§ã¯ãHPVã¯ã¯ãã³ã«é¢ãã蚎èšã倿°é²ããããŠããŸããæ³åŸäºåæã®HPã§ãªã³ã¯ãããŠãã蚎ç¶ããããã¬ãŒãã·ã«ãã®åé¡ç¹ãæãèµ·ãããŸããã
ã¢ã¡ãªã«ã§ã®èšŽèš
ååããã®ç¶ãã§ãã
Wisner Baumæ³åŸäºåæã®HPã«ã¯ãHPVã¯ã¯ãã³èšŽèšã®èšŽç¶ãå ¬éãããŠããŸãã
Caroline Canteraããã®èšŽèš
ã¬ãŒãã·ã«åŸã®å·å®³ïŒåå®®é žãã
æåºæ¥: 2023 幎 3 æ 16 æ¥
U.S. District Court for the Western District of North Carolina (Case No. 3:23-cv-00161, MDL No. 3036)
æ¿èªå¯©æ»æéã®ççž®
蚎ç¶ã®é ç®ããæ°ã«ãªããã®ãåãäžããŸãã
B. Overview of the Gardasil Vaccine and Its Fast-Tracked Approval
The FDA approved Gardasil on June 8, 2006, after granting Merck fast-track status and speeding the approval process to a six-month period, leaving unanswered material questions relating to its effectiveness and safety as well as when and to whom the Gardasil vaccine ought to be administered.
ã¡ã«ã¯ç€Ÿã®ã¬ãŒãã·ã«ã¯ãFDAã§åªå 審æ»ãåãããããfast-trackãã«æå®ãããæå¹æ§ãå®å šæ§ã«é¢ãã質åã«ãã¡ããšçããªããŸãŸãïŒéåžž10ã¶æãããïŒå¯©æ»ã6ã¶æã«ççž®ããŠæ¿èªããããšæžãããŠããŸãã
ã¬ãŒãã·ã«ã®å¯©æ»ã®æç³»åã¯ãäžèšã«ãæžãããŠããŸãã
fast-trackã«ã€ããŠã¯ãFDAã®ãµã€ãã«ã説æããããŸãã
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.
ãé節ãªçç¶ãæ²»çããå»çããŒãºãæºããå»è¬åã®éçºãä¿é²ãã審æ»ãè¿ éåããããšãç®çãšããããã»ã¹ããšã®ããšã§ãããäºé²ã®ããã®ã¬ãŒãã·ã«ã«ãããåœãŠã¯ãŸãã®ã§ããããã
ã³ããã¯ã¯ãã³ã¯ç·æ¥äœ¿çšèš±å¯ïŒEUAïŒã§ãããããã以å€ã«ããã®ãããªããã»ã¹ãããããšãåããŠç¥ããŸããã
蚎ç¶ã«ã¯ãFDAã®æ¿èªåŸã«CDCã§ãæšå¥šããããšãããŸãããåœæ CDCã®æé·ã ã£ãJulie GerberdingïŒ2002幎ïœ2009幎ïŒãã2010幎ã«ã¡ã«ã¯ç€Ÿã®ã¯ã¯ãã³äºæ¥éšç€Ÿé·ã«å°±ä»»ããããšãæžãããŠããŸãã
2016幎ã«å®æœãããã¡ã«ã¯ç€Ÿã®ãã¬ããã£ã³ããŒã³ã§ã¯å ç«¥ãå©çšãããCDCãæšå¥šããŠããããšããæåããããŸãã

åå®®é žããã®äºé²å¹æ
F. Merck Has Systematically Misrepresented the Efficacy of Gardasil ByãAdvertising that Gardasil Prevents Cervical Cancer When There Are No Clinical Studies to Support This False Claim
ãã®éšåã§ã¯ãã¬ãŒãã·ã«ãåå®®é žãããäºé²ããããšãè£ä»ããèšåºè©Šéšãè¡ã£ãŠããªãããšã«ã€ããŠæžãããŠããŸãã
Because it can take decades for a persistent HPV infection to proceed to
development of cervical cancer, and because cervical cancer is so rare, a true efficacy study would require decades and likely hundreds of thousand â if not millions â of trial participants to demonstrate that eliminating certain HPV infections would actually prevent the development of cervical cancer.
æç¶æ§HPVææãåå®®é žããã®çºçã«é²ãã«ã¯æ°å幎ãããå¯èœæ§ããããçã®æå¹æ§ç ç©¶ã«ã¯ãæ°åå¹Žãæ°åäžäººã®æ²»éšåå è ãå¿ èŠãšãªãã ãããšæžãããŠããŸãã
ç§ããåå®®é žããã¯ã¯ãã³ã®äºé²å¹æã¯èšåºè©Šéšã ãã§ç€ºãããšã¯ã§ããªããšæã£ãŠããŸããã10æ³ã®åãæ¥çš®ããŠãæ°å¹ŽHPVã®ææãé²ãããšãã§ãããšããŠãã30代ã40代ã50代ã§çºçããªãããšã®èšŒæã«ã¯ãªããŸããã確èªã§ããŠããªãã®ã«ããªãæ°å¹Žã®èšåºè©Šéšã ãã§ãåå®®é žãããäºé²ããã¯ã¯ãã³ããšèšã£ãŠçºå£²ããããšãèš±ãããã®ã§ããããã
æ¥æ¬ã®ã¬ãŒãã·ã«ã®æ·»ä»ææžã«ãããäºé²å¹æã®æç¶æéã¯ç¢ºç«ããŠããªãããšæžãããŠããŸãã

åãã¡ã«ã¯ç€ŸããåºãŠãã9䟡ã®ã·ã«ã¬ãŒããåæ§ã§ãã

H. As it Did with Vioxx, In Conducting Its Clinical Trials, Merck Concealed Risks to Falsely Enhance the Safety Profile of Gardasi
ii. Merck Used a Highly Toxic âPlaceboâ to Mask Gardasil Injuries
Instead of comparing health outcomes among volunteers in the Gardasil study group to health outcomes among volunteers receiving an inert placebo, Merck purposefully used a highly toxic placebo as a control in order to conceal Gardasilâs risks in all trials using comparators with the exception of Protocol 018, where only 372 children received a non-saline
placebo containing everything in the vaccine except the adjuvant and antigen.
ã¡ã«ã¯ç€Ÿã¯èšåºè©Šéšã§ãã»ãšãã©ã®ãã©ã»ã矀ã«ççé£å¡©æ°Žã䜿ã£ãŠããªãã£ããšæžãããŠããŸãã
æ¥æ¬ã§ã®ã¬ãŒãã·ã«ã®å¯©æ»å ±åæžã確èªããŸããã



ãã©ã»ãïŒ225ïŒïŒã¢ã«ãããŠã ã¢ãžã¥ãã³ã225ÎŒg
ãã©ã»ãïŒ450ïŒïŒã¢ã«ãããŠã ã¢ãžã¥ãã³ã450ÎŒg
ãã©ã»ãïŒ0ïŒïŒã¢ã«ãããŠã ã¢ãžã¥ãã³ãé嫿
ãã©ã»ãïŒ0ïŒã«ã¯ã¢ãžã¥ãã³ãé嫿ãšããããŠããŸããããã以å€ã«ã¯ã¢ãžã¥ãã³ããå ¥ã£ãŠããŸããããã¯ãã©ã»ã矀ãšèšããã§ããããã

ã¢ãžã¥ãã³ãæåã¯ãæ°æ·»å ç©ãšæžãããŠããŸãããããé»å¡ãç¥ãã

害ããããæ¯èŒããããã®ãã©ã»ã矀ã«ãæ¯æ§ããããããããªãã¢ãžã¥ãã³ãã䜿çšããããæ¯èŒè©Šéšã«ã¯ãªããŸããã
ãããªèšåºè©Šéšã§ãå®å šæ§ã確èªãããšèšããã§ããããã蚎ç¶ã«ã¯ããã®ã¢ãžã¥ãã³ããæå®³ã§ããçç±ãªã©ãæžãããŠããŸãã
ãã®ãããªãã©ã»ã矀ã䜿ã£ãæ¯èŒè©Šéšãããªãèš±ãããã®ã§ããããã
ãã®ã»ãã審æ»å ±åæžãèŠããšå®æœãããŠããªã詊éšããããŸããã

ã¢ã¡ãªã«ã§ã¯ãã¬ãŒãã·ã«ããµãŒããªãã¯ã¹ããã§ã«è²©å£²çµäºãšãªã£ãŠãããçŸåšäœ¿ãããŠããã®ã¯ã·ã«ã¬ãŒã9ïŒã¢ã¡ãªã«ã§ã¯ã¬ãŒãã·ã«9ïŒã®ã¿ã§ããã«ããããªãŒã¹ãã©ãªã¢ããã¬ãŒãã·ã«ããã·ã«ã¬ãŒã9ã«åãæ¿ããŠããããã§ããã¢ã¡ãªã«ãªã©ã§ããæµéããŠããªããªããæ¥æ¬çšã«ããããäœããšã¯æããŸããã
æ¥æ¬ã§äœ¿ãããŠãããã®ã¯ãåšåº«åŠåãªã®ã§ã¯ãªãã§ãããããããããããçšåºŠã¯ããããæ¥æ¬ã§ãã·ã«ã¬ãŒã9ã®ã¿ã«ããã€ãããªã®ã§ã¯ãªãã§ãããããæ©ã䜿ã£ãŠããŸããããããç·åã«ãå ¬è²»ã§ã®æ¥çš®ãéå§ããããã«æããŸãã
ã·ã«ã¬ãŒã9ã¯å®å šæ§ã®é¢ã§æ¹åããããšãããã€ãŒããèŠãããŸãããããã§ã¯ãªããšæããŸããããããã¬ãŒãã·ã«ä»¥äžã«å®å šæ§ã確èªããŠããªããšæããŸãã

æ°æ·»å å€ã«ã€ããŠããæ¬æ·»å å€ã®å埩æäžæ¯æ§è©Šéšã«ãããŠå埩æ§ã¯èªãããããã®ã®ãäžè¬ã«ã¢ãžã¥ãã³ãæäžã«ããèªããããæäžéšäœã«ããã倿§ã䌎ãççæ§æèŠãèªãããããããã©ãææäºé²ã¯ã¯ãã³ã®ã¢ãžã¥ãã³ããšããŠã®äœ¿çšã¯ãåé¡ãªããšå€æããããšæžãããŠããŸãã
ããã«ãã»ãšãã©ãççé£å¡©æ°Žã§ã¯ãªããã¬ãŒãã·ã«ãªã©ã§æ¯èŒè©Šéšãè¡ã£ãŠããŸããå®å šæ§ãçåèŠãããŠããã¬ãŒãã·ã«ãšæ¯èŒããŠãå®å šæ§ã確èªã§ããã§ããããããªãççé£å¡©æ°Žã§æ¯èŒããªãã®ã§ãããããççé£å¡©æ°Žãšæ¯èŒããããå®å šã§ã¯ãªããšããçµæãã§ããããšããæããŸãããããã§ã審æ»ã«éã£ãŠããŸããªããã審æ»ã§æ¿èªããããïŒãå®å šããšã¯ãããªããšæããŸãã



ãã®ãããªèšåºè©Šéšã§æ¿èªããããã®ãããªãå®å šã ãšæèšã§ããã®ã§ããããã
ããã«ãæ·»ä»ææžã«ã¯äºææ§ã«é¢ããå®å šæ§ãªã©ã®ããŒã¿ã¯ãªããšæžãããŠããŸãã以åã«ãµãŒããªãã¯ã¹ãã¬ãŒãã·ã«ãæ¥çš®ãã人ã«ãã·ã«ã¬ãŒã9ãæ¥çš®ããããšãã§ãããšèšã£ãŠããå»çæ©é¢ããããŸããã補è¬äŒç€Ÿã¯ãããŒã¿ã¯ãªãããšæžããŠããŸãã

æ¥çš®åŸã®å¥åº·è¢«å®³ã¯ã誰ã«èµ·ãããããããŸãããããæ¥çš®ãè¿·ã£ãŠãããªãã被害è ã®äœéšè«ã蚎ç¶ã«ãç®ãéããŠãæ¥çš®ãã人ã«ã©ã®ãããªããšãèµ·ãããããããæ¬åœã«æ¥çš®ãšé¢ä¿ããªããšãããã®ããèªåã§ç¢ºãããããšã倧åã ãšæããŸãã